Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy
United States34 participantsStarted 2026-05-01
Plain-language summary
The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults. It will also learn about the safety of EUS guided embolization. The main questions it aims to answer are:
1. Does EUS guided embolization maintain an acceptable safety profile?
2. Does EUS guided embolization of large SPSS result in significant clinical improvement in patients with refractory hepatic encephalopathy?
Participants will:
1. Receive EUS guided embolization or medical management.
2. Receive follow-up EUS procedures one month after embolization for assessment of the shunt patency and development of varices (embolization group).
3. Receive follow-up every week for 4 weeks to assess degree of worst episode of hepatic encephalopathy via West Haven criteria.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adults aged ≥18 years with known cirrhosis
✓. MRHE; defined as ≥2 episodes of hepatic encephalopathy, HE (as documented in an outpatient office visit or during an inpatient admission) within 6 months prior to enrollment despite medical therapy with lactulose and rifaximin
✓. Admission to inpatient hepatology floor at University Hospital-Newark with MRHE at the time of enrollment
✓. Presence of a spontaneous portosystemic shunt; confirmed on CT/MRI at the index admission.
Exclusion criteria
✕. Severe/refractory ascites defined as ascites that does not recede after medical therapy or reoccurs shortly after fluid has been removed
✕. Refractory or recurrent bleeding from esophageal varices
✕. Presence of portal vein thrombosis with complete occlusion
✕. Hepatocellular carcinoma beyond Milan criteria or other advanced malignancy with limited life expectancy (\<6 months)
✕
What they're measuring
1
The severity of hepatic encephalopathy
Timeframe: 4 weeks after intervention
Trial details
NCT IDNCT07553858
SponsorRutgers, The State University of New Jersey